2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

2 trials found

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000325-26-FR (EUCTR)	29/04/2021	19/02/2021	Phase 2 safety and tolerability study using ANX005 for ALS	Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Intravenous ANX005in Su ...	Amyotrophic Lateral Scelrosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: IMMUNOGLOBULIN G	Annexon Biosciences	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	25	Phase 2	United States;France;Canada
2	NCT04569435 (ClinicalTrials.gov)	January 15, 2021	23/9/2020	Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)	A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ...	Amyotrophic Lateral Sclerosis	Drug: ANX005	Annexon, Inc.	NULL	Recruiting	18 Years	N/A	All	24	Phase 2	United States;Canada;France

First Previous1Next Last